Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia

NCT05319249 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL: NK cells
DRUG: Talazoparib 1 MG [Talzenna]

Sponsor

German Cancer Research Center